MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

Search

Smith & Nephew PLC ADR

Geschlossen

33.09 1.01

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

32.76

Max

33.28

Schlüsselkennzahlen

By Trading Economics

Einkommen

296M

Verkäufe

3B

KGV

Branchendurchschnitt

29.196

89.037

Dividendenrendite

2.33

Gewinnspanne

9.895

Angestellte

17,000

EBITDA

723M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+3.72% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

2.33%

2.18%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

14B

Vorheriger Eröffnungskurs

32.08

Vorheriger Schlusskurs

33.09

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Smith & Nephew PLC ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

22. Jan. 2026, 21:55 UTC

Ergebnisse

Capital One Financial Posts Higher 4Q Profit As Lending Increases

22. Jan. 2026, 23:52 UTC

Ergebnisse

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

22. Jan. 2026, 23:48 UTC

Market Talk

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

22. Jan. 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Profit-Taking -- Market Talk

22. Jan. 2026, 23:40 UTC

Market Talk

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

22. Jan. 2026, 23:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22. Jan. 2026, 23:30 UTC

Market Talk

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

22. Jan. 2026, 22:37 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

22. Jan. 2026, 21:59 UTC

Akquisitionen, Fusionen, Übernahmen

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

22. Jan. 2026, 21:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

22. Jan. 2026, 21:44 UTC

Ergebnisse

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

22. Jan. 2026, 21:32 UTC

Akquisitionen, Fusionen, Übernahmen

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

22. Jan. 2026, 21:31 UTC

Akquisitionen, Fusionen, Übernahmen

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

22. Jan. 2026, 21:31 UTC

Akquisitionen, Fusionen, Übernahmen

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

22. Jan. 2026, 21:30 UTC

Akquisitionen, Fusionen, Übernahmen

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

22. Jan. 2026, 21:30 UTC

Ergebnisse

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

22. Jan. 2026, 21:30 UTC

Akquisitionen, Fusionen, Übernahmen

Capital One To Acquire Brex >COF

22. Jan. 2026, 21:13 UTC

Ergebnisse

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

22. Jan. 2026, 21:11 UTC

Ergebnisse

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

22. Jan. 2026, 21:11 UTC

Ergebnisse

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

22. Jan. 2026, 21:10 UTC

Ergebnisse

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

22. Jan. 2026, 21:06 UTC

Ergebnisse

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

22. Jan. 2026, 21:05 UTC

Ergebnisse

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

22. Jan. 2026, 21:05 UTC

Ergebnisse

Capital One 4Q Rev $15.58B >COF

22. Jan. 2026, 21:05 UTC

Ergebnisse

Capital One 4Q EPS $3.26 >COF

22. Jan. 2026, 21:05 UTC

Ergebnisse

Capital One 4Q Net Interest Margin 8.26% >COF

22. Jan. 2026, 21:05 UTC

Ergebnisse

Capital One 4Q Net $2.13B >COF

22. Jan. 2026, 21:05 UTC

Ergebnisse

Capital One 4Q Adj EPS $3.86 >COF

22. Jan. 2026, 21:05 UTC

Ergebnisse

Capital One 4Q Net Charge-Offs $3.8B >COF

22. Jan. 2026, 21:05 UTC

Ergebnisse

Intuitive Surgical 4Q EPS $2.21 >ISRG

Peer-Vergleich

Kursveränderung

Smith & Nephew PLC ADR Prognose

Kursziel

By TipRanks

3.72% Vorteil

12-Monats-Prognose

Durchschnitt 34 USD  3.72%

Hoch 34 USD

Tief 34 USD

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Smith & Nephew PLC ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

1 ratings

0

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

26.64 / 28.37Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat